SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002; 13: 10071015.
  • 2
    World Health Organization. International classification of tumors: histological typing of upper respiratory tract tumors. Geneva: World Health Organization, 1991.
  • 3
    Teo PM, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 1996; 77: 24232431.
  • 4
    Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 2002; 25: 219223.
  • 5
    Thephamongkhol K, Browman G, Wong R, et al. Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: a meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases [abstract 5522]. Proc Am Soc Clin Oncol. 2004; 23: 491.
  • 6
    Lee AW, Tung S, Chua D, et al. Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1-4N2-3M0 nasopharyngeal carcinoma (NPC) [abstract 5506]. Proc Am Soc Clin Oncol. 2004; 23.
  • 7
    Wee J, Tai BC, Wong HB, et al. Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety [abstract 5500]. Proc Am Soc Clin Oncol. 2004; 23: 487.
  • 8
    Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004; 22: 26432653.
  • 9
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 13101317.
  • 10
    Hoffman H, Weber R, Ang K, et al. Changing patterns of practice in the management of nasopharynx carcinoma (NPC): analysis of the National Cancer Database (NCDB) [abstract 5501]. Proc Am Soc Clin Oncol. 2004; 23: 487.
  • 11
    Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002; 20: 20382044.
  • 12
    Chan A, Teo P, Leung S, et al. Final results of a phase III randomized study of concurrent weekly cisplatin-RT versus RT alone in locoregionally advanced nasopharyngeal carcinoma (NPC) [abstract 5523]. Proc Am Soc Clin Oncol. 2004; 23: 492.
  • 13
    Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21: 631637.
  • 14
    Bonner J, Harari P, Cohen R, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract 5507]. Proc Am Soc Clin Oncol. 2004; 23.
  • 15
    Ma B, Poon T, To KF, et al. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma. Head Neck. 2003; 25: 864872.
  • 16
    Fountzilas G, Daniilidis J, Sridhar KS, et al. Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. Cancer. 1990; 66: 14531460.
  • 17
    Bachouchi M, Cvitkovic E, Azli N, et al. High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst. 1990; 82: 616620.
  • 18
    Dimery IW, Peters LJ, Goepfert H, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol. 1993; 11: 19191928.
  • 19
    Fonseca E, Cruz JJ, Rodriguez CA, et al. Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma. J Infus Chemother. 1996; 6: 217220.
  • 20
    Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 43054313.
  • 21
    Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995; 33: 569577.
  • 22
    Roussy IG. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996; 35: 463469.
  • 23
    Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer Epidemiol Biomarkers Prev. 1998; 83: 22702283.
  • 24
    Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 13501357.
  • 25
    Hareyama M, Sakata K, Shirato H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer. 2002; 94: 22172223.
  • 26
    Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 2000; 1: 8693.
  • 27
    Chua D, Ma J, Sham J. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials [abstract 5524]. Proc Am Soc Clin Oncol. 2004; 23: 492.
  • 28
    Chan AT, Ma B, Lo D, et al. A phase II study of neoadjuvant taxol and carboplatin followed by concurrent cisplatin-radiotherapy in locoregionally advanced nasopharyngeal carcinoma with EBV DNA monitoring. J Clin Oncol. 2004; 22: 18.
  • 29
    Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002; 20: 18451852.
  • 30
    Oh J, Vokes E, Kies M, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced nasopharyngeal cancer. Ann Oncol. 2002; 14: 565569.
  • 31
    Johnson FM, Palmer JL, Kies M, et al. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004; 100: 991998.
  • 32
    Yamouni M, Benhadji K, Lahfa I, et al. A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of nasopharyngeal type (UCNT) [abstract 5599]. Proc Am Soc Clin Oncol 2004; 23: 511.
  • 33
    Adane S, Mekki F, Bouzid K. Gemcitabine (G) plus cisplatin (C) plus radiotherapy in first-line treatment of locally advanced and metastatic undifferentiated carcinoma of the nasopharyngeal type (UCNT): preliminary results of a phase II study [abstract 5618]. Proc Am Soc Clin Oncol. 2004; 23: 515.
  • 34
    Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988; 6: 14011410.
  • 35
    Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002; 52: 12381244.
  • 36
    Chua DT, Kwong DL, Sham JS, et al. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer. 2000; 36: 736741.
  • 37
    Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore. 1991; 20: 601603.
  • 38
    Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994; 5: 8789.
  • 39
    Boussen H, Cvitkovic E, Wendling JL, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol. 1991; 9: 16751681.
  • 40
    Su WC, Chen TY, Kao R, et al. Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology. 1993; 50: 205208.
  • 41
    Taamma A, Fandi A, Azli N, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer. 1999; 86: 11011108.
  • 42
    Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol. 1998; 16: 25142521.
  • 43
    Hasbini A, Mahjoubi R, Fandi A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol. 1999; 10: 421425.
  • 44
    Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol. 1998; 9: 327329.
  • 45
    Yeo W, Leung TW, Chan AT, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998; 34: 20272031.
  • 46
    Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999; 10: 235237.
  • 47
    Airoldi M, Pedani F, Marchionatti S, et al. Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori. 2002; 88: 273276.
  • 48
    Fountzilas G, Skarlos D, Athanassiades A, et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 1997; 8: 451455.
  • 49
    McCarthy J, Tannock I, Degendorfer P, et al. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002; 38: 686690.
  • 50
    Chua DT, Sham J, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2004; 39: 361366.
  • 51
    Jiang Y, Deng MQ, Guo L, et al. [Phase I clinical trial evaluation of capecitabine in concurrent combination of radiotherapy in nasopharyngeal carcinoma]. Ai Zheng 2004; 23: 461466.
  • 52
    Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002; 95: 25162523.
  • 53
    Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002; 13: 150156.
  • 54
    Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002; 13: 12521258.
  • 55
    Leong S, Wee J, Tan T, et al. Phase II study of gemcitabine, paclitaxel and carboplatin in patients with metastatic nasopharyngeal carcinoma -updated results [abstract 2001]. Proc Am Soc Clin Oncol. 2003; 23.
  • 56
    Zhang L, Zhao C. Randomized phase II clinical study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locally advanced nasopharyngeal carcinoma: preliminary result [abstract 2003]. Proc Am Soc Clin Oncol. 2003; 22: 498.
  • 57
    Poon D, Leong S, Cheung Y, et al. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC) [abstract 5576]. Proc Am Soc Clin Oncol 2004; 23: 505.
  • 58
    Pang R, Poon T, Chan ATC, et al. Studies on anti-tumor effect of C225, a monoclonal anti-epidermal growth factor receptor antibody, on nasopharyngeal carcinoma [abstract 823]. Proc Am Assoc Cancer Res. 2003; 44.
  • 59
    Chan ATC, Hsu M, Goh B, et al. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy [abstract 2000]. Proc Am Soc Clin Oncol. 2003; 23.
  • 60
    Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol. 2002; 29(5 Suppl 14 ): 1830.
  • 61
    Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 535542.
  • 62
    Stein ME, Ruff P, Weaving A, et al. A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa. Am J Clin Oncol. 1996; 19: 386388.
  • 63
    Yeo W, Leung TW, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 1996; 38: 466470.
  • 64
    Chi KH, Chan WK, Cooper DL, et al. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer. 1994; 73: 247252.